The Lifecore Webster acquisition agreement gives Lifecore Biomedical (NASDAQ: LFCR) an upfront cash value of $6.28 per share, plus contingent rights that could lift the total consideration if future performance milestones are met.
Webster Equity Partners valued the transaction at as much as $663.7 million assuming full milestone achievement. Lifecore expects the acquisition to close near the end of the fourth quarter of 2026, subject to shareholder and regulatory approvals.
Lifecore Webster Acquisition Includes Contingent Payments
The $6.28 closing payment represents a 49.5% premium to Lifecore’s September 25 closing price, according to the company’s official SEC filing and transaction announcement.
Common shareholders and holders of Series A preferred stock would also receive non-tradeable contingent value rights, or CVRs. Those rights can produce up to $160 million of aggregate additional cash payments tied to specified business-performance milestones.
If every milestone is achieved, Lifecore said the combined value could reach $9.67 per common-share equivalent. That maximum is not guaranteed: the CVRs may pay less or nothing if the defined targets are missed.
Go-Shop Period Leaves Room for Competing Offers
The agreement includes a 30-day go-shop period during which Lifecore and its advisers may solicit alternative proposals. The board can consider a superior offer under the merger agreement’s terms, so Webster’s transaction is signed but not yet final.
Webster has secured committed debt and equity financing for the purchase. The deal is not subject to a separate financing condition, although it still depends on the other closing requirements and could be delayed if regulatory reviews take longer than expected.
Lifecore develops and manufactures injectable pharmaceutical products, including formulations using hyaluronic acid. Webster focuses on health-care investments, making the acquisition a move to take a public contract-development and manufacturing business private.
The shareholder-vote timetable, any competing bid during the go-shop period and the precise CVR milestones will shape the final economics. Until the transaction closes, Lifecore remains publicly traded and continues to report as an independent company.
